World's Best Scientists 2026 revealed!

Overview

John A. Thompson is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research primarily focuses on the field of Medicine, with particular emphasis on Oncology, Immunology, Genetics, Epidemiology, and Pulmonary and Respiratory Medicine.

The scientist's work extensively covers topics related to cancer and immune system interactions. Key areas of research include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Colorectal Cancer Treatments and Studies
  • Immunotherapy and Immune Responses
  • Microscopic Colitis
  • Inflammatory Bowel Disease

A number of recent publications illustrate the scope and focus of their work. These include:

  • "NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020" (2020), Journal of the National Comprehensive Cancer Network
  • "Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology" (2022), Journal of the National Comprehensive Cancer Network
  • "NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021" (2021), Journal of the National Comprehensive Cancer Network
  • "Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy" (2020), Annals of Oncology
  • "Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma" (2023), Journal of Clinical Oncology

Their frequent coauthors include Yinghong Wang, Shailender Bhatia, Anusha Shirwaikar Thomas, Jeffrey A. Sosman, and Fangwen Zou.

John A. Thompson has published work in several scientific journals, with the most frequent venues being:

  • Journal of Clinical Oncology
  • Journal of the National Comprehensive Cancer Network
  • Journal for ImmunoTherapy of Cancer
  • Annals of Oncology
  • Supportive Care in Cancer

Best Publications

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

    Charles M. Balch;Seng-Jaw Soong;Jeffrey E. Gershenwald;John F. Thompson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

    Filipe Martins;Filipe Martins;Latifyan Sofiya;Gerasimos P. Sykiotis;Faiza Lamine

  • Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

    C. Yee;C. Yee;J. A. Thompson;J. A. Thompson;D. Byrd;D. Byrd;S. R. Riddell;S. R. Riddell

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

    Peter P. Lee;Cassian Yee;Peter A. Savage;Lawrence Fong

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

    Naomi N. Hunder;Herschel Wallen;Jianhong Cao;Deborah W. Hendricks

  • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

    Jeffrey Weber;John A. Thompson;Omid Hamid;David Minor

  • Management of Immunotherapy-Related Toxicities, Version 1.2019.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

    Cassian Yee;John A. Thompson;Patrick Roche;David R. Byrd

  • An Evidence‐based Staging System for Cutaneous Melanoma

    Charles M. Balch;Seng Jaw Soong;Michael B. Atkins;Antonio C. Buzaid

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

    Bryan J Schneider;Jarushka Naidoo;Bianca D Santomasso;Christina Lacchetti

  • A new American Joint Committee on Cancer staging system for cutaneous melanoma.

    Charles M. Balch;Antonio C. Buzaid;Michael B. Atkins;Natale Cascinelli

  • Cutaneous melanoma, version 2.2019

    Daniel G. Coit;John A. Thompson;Mark R. Albertini;Christopher Barker

  • Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics

    Kelly G. Paulson;Kelly G. Paulson;Song Youn Park;Natalie A. Vandeven;Kristina Lachance

  • NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.

    Julie R. Brahmer;Christina Lacchetti;Christina Lacchetti;Christina Lacchetti;John A. Thompson;John A. Thompson;John A. Thompson

Frequent Co-Authors

Michael B. Atkins
Michael B. Atkins Georgetown University
Kim Margolin
Kim Margolin City Of Hope National Medical Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
F. Stephen Hodi
F. Stephen Hodi Harvard University
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Merrick I. Ross
Merrick I. Ross The University of Texas MD Anderson Cancer Center
Vernon K. Sondak
Vernon K. Sondak University of South Florida
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
William E. Carson
William E. Carson The Ohio State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in Medicine or healthcare in the USA, online degrees offer flexible options for your academic journey. For those already in nursing, there are numerous phd nursing programs online designed to help further your expertise and open doors to leadership, research, or advanced clinical roles.

Cost is a significant factor for many students. Finding what is the cheapest rn to bsn program online can make progressing from RN to BSN more accessible and affordable. Accelerated learning is also important—options like the cheapest direct entry msn programs are available for those who hold a non-nursing bachelor’s degree but wish to transition quickly into advanced nursing roles.

Admission requirements vary, and some aspiring students may be looking for direct admit nursing programs that offer a more streamlined application process. Exploring all pathways can help you make informed decisions tailored to your academic goals and financial situation.

Best Scientists Citing John A. Thompson

Trending Scientists

Recently Published Articles